Bayer: promising treatment for non-Hodgkin's lymphoma

(CercleFinance.com) - Bayer has announced that a phase III trial has shown the efficacy of the combination of copanlisib and rituximab in patients with relapsed indolent non-Hodgkin's lymphoma (NIL).


Treated patients had a 48% lower risk of disease progression or death compared to patients treated with rituximab and placebo.

According to Pier Luigi Zinzani of the Institute of Haematology and Medical Oncology at the University of Bologna in Italy, this data shows a much-needed advance in the treatment paradigm.


Copyright (c) 2021 CercleFinance.com. All rights reserved.